A Study to Evaluate MWN109 Tablets in Healthy Adult Participants

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

May 31, 2026

Conditions

Overweight or Obesity

Interventions

DRUG

MWN109 tablet

Strength: 7.5mg, 15mg, 30mg, and 45 mg; Administration: Oral.

DRUG

Placebo

Administration: Oral.

Trial Locations (1)

CMAX Clinical Research, Adelaide

All Listed Sponsors

lead

Shanghai Minwei Biotechnology Co., Ltd

INDUSTRY